AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aldeyra Therapeutics Receives Buy Rating from JonesTrading with $9.00 Price Target
ByAinvest
Sunday, Aug 10, 2025 12:58 am ET1min read
Aldeyra Therapeutics (ALDX) received a Buy rating from JonesTrading analyst Catherine Novack, with a price target of $9.00. Novack has a 37.39% success rate on recommended stocks. The analyst consensus on ALDX is a Strong Buy with an average price target of $8.75. The company reported a quarterly GAAP net loss of $9.93 million, compared to $8.08 million last year.
Aldeyra Therapeutics Inc. (ALDX), a biotechnology company focused on immune-mediated and metabolic diseases, recently reported its Q2 2025 earnings. The company posted a quarterly GAAP net loss of $9.93 million, compared to $8.08 million in the same period last year. Despite the loss, analysts remain optimistic about Aldeyra's prospects.Catherine Novack, a JonesTrading analyst, gave Aldeyra a Buy rating with a price target of $9.00. Novack's success rate on recommended stocks is 37.39%. The analyst consensus on ALDX is a Strong Buy, with an average price target of $8.75. Analysts expect a rise in quarterly revenue, with estimates suggesting revenue of $1.083 million for the period ending September 30, 2025 [2].
Aldeyra's financial health remains robust, with $90.1 million in cash, cash equivalents, and marketable securities as of May 14, 2025. The company believes this funding will be sufficient to support its operations through 2027. Aldeyra's pipeline includes several promising drug candidates, such as Reproxalap for dry eye disease and ADX-248 for moderate alcohol-associated hepatitis [1].
While Aldeyra reported a net loss, the company's strong financial position and promising pipeline have analysts bullish on its future prospects. The company continues to invest in innovative therapies that modulate protein systems, aiming to optimize multiple pathways while minimizing toxicity.
References:
[1] https://www.marketscreener.com/news/aldeyra-therapeutics-corporate-overview-8727b2-ce7c5edbdf8af326
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U03YH:0-aldeyra-therapeutics-inc-expected-to-post-a-loss-of-25-cents-a-share-earnings-preview/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet